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Hyperplasiaofairwaysmoothmuscle(ASM)isafeatureoftheremodelledairwayinasthmatics.Weexaminedtheantiproliferative
eﬀectiveness of the corticosteroid dexamethasone on expression of the key regulator of G1 cell cycle progression—cyclin D1—in
ASM cells from nonasthmatics and asthmatics stimulated with the mitogen platelet-derived growth factor BB. While cyclin D1
mRNA and protein expression were repressed in cells from nonasthmatics in contrast, cyclin D1 expression in asthmatics was
resistant to inhibition by dexamethasone. This was independent of a repressive eﬀect on glucocorticoid receptor translocation.
Our results corroborate evidence demonstrating that corticosteroids inhibit mitogen-induced proliferation only in ASM cells from
subjects without asthma and suggest that there are corticosteroid-insensitive proliferative pathways in asthmatics.
1.Introduction
Asthma is a chronic inﬂammatory condition of the lung
associated with structural remodelling of the airway wall.
As a consequence of long-term exposure to inﬂammatory
mediators, the airways of asthmatics become remodelled.
Airway smooth muscle mass is increased, and neovascular-
izationisevidentinthesubepithelialmucosa.Airwayﬁbrosis
becomes apparent, with thickening of the lamina reticularis
and increased interstitial extracellular matrix deposition
being typical features of an asthmatic airway [1]. Although
numerous cell types contribute to airway remodelling, the
increase in airway smooth muscle mass is considered to have
the largest impact on airway narrowing in asthma [2–4].
Inhaled corticosteroids are a ﬁrst-line anti-inﬂammatory
therapy in asthma. However, as many asthmatics manifest
persistent airway hyperresponsiveness even after prolonged
corticosteroid therapy [5], corticosteroid resistance and
insensitivity is known to exist [6]. Although corticosteroids
can inhibit some aspects of remodelling [7], we do not
yet know whether ASM mass is reduced by corticosteroid
treatment in vivo. Interestingly, Roth et al. [8] demonstrated
that ASM proliferation in cells derived from asthmatics is
resistant to inhibition by corticosteroids, suggesting that
the proliferative pathways underlying the hyperplastic ASM
phenotype in asthmatics are corticosteroid insensitive.
In this study, we continue investigations into corticos-
teroid insensitivity in vitro by examining the eﬀect of dex-
amethasone on a key regulator of G1 cell cycle progression,
cyclin D1, in ASM cells from asthmatics and nonasthmatics.
Cyclin D1 has been the most widely studied cyclin in ASM
biology using cells from nonasthmatics [4, 9, 10]a n dm o r e
recently asthmatics [11]. Our study examines cyclin D1
mRNA and protein expression in ASM cells from asthmatics
and demonstrates that cyclin D1 upregulation is insensitive
to corticosteroid inhibition.
2.MaterialsandMethods
2.1. Cell Culture. H u m a nA S Mc e l l sw e r eo b t a i n e df r o m
subjects without and with asthma by methods adapted
from those previously described [12, 13], in accordance
with procedures approved by the Sydney South West Area
Health Service and the Human Research Ethics Committee
of the University of Sydney. A minimum of three diﬀerent
ASM primary cell lines were used for each experiment.2 Journal of Allergy
Table 1: Subject demographics.
Subject no. Gender Disease FEV1 (% Pred) FVC (% Pred) FEV1:FVC (%) Smoker Height Weight Experiments
1F Ca 1, 2
2F A 64% 70% 76% Ex-smoker 1, 3
3F Ca 1, 2
4M A 82% No 1, 3
5F NSCCa Yes 1, 2
6F A 2.04L 2.5L No 158cm 64kg 1, 3
7M NSSCa 2.12L 3.35L Ex-smoker 173cm 76kg 1, 2
8F A 1.87L 2.32L No 168cm 57kg 1, 3
9F Bronchiolitis
obliterans
1, 2
10 M A 3.75L 5.9L No 179cm 110kg 1, 3
11 M Emphysema 1, 2
12 M A No 1, 3
13 F Emphysema Yes 1, 2
14 M A 4.77 L 5.32L Yes 1, 3
15 F Emphysema 27% (0.51 L) 67% (1.5L) 153cm 1, 2
16 M Emphysema, α-1
antitrypsin deﬁciency
15% (0.61 L) 66% (3.42L) 4
17 M A 57% 61% 77% No 4
18 M COPD 20% 65% 24% Yes 4
19 M Ca + A Ex-smoker 4
20 M Ca 1.95L 2.5L Ex-smoker 169cm 79kg 4
21 M A 4
Abbreviations used: Ca, carcinoma; A, asthma; NSCCa, nonsmall cell carcinoma; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in 1 second (% predicted); FVC, forced vital capacity (% predicted).
All the subjects’ disease states were conﬁrmed by doctor
diagnosis, and subject demographics are shown in Table 1.
Unless otherwise speciﬁed, all chemicals used in this
study were purchased from Sigma-Aldrich (St. Louis, MO).
2.2.CyclinD1mRNAExpression. Toexaminethetimecourse
of induction of cyclin D1 mRNA expression by platelet-
derived growth factor BB (PDGF-BB) and repression by
dexamethasone, growth-arrested ASM cells from n = 8
nonasthmatic and n = 7 asthmatic subjects were pretreated
for 1h with 100nM dexamethasone, compared to vehicle.
CellswerethenstimulatedwithPDGF-BB(25ng/mL:Merck,
Darmstadt, Germany) for 0, 2, 4, 8, and 24h, and cyclin D1
mRNA expression was quantiﬁed by real-time RT-PCR as
previously described [14].
2.3. Cyclin D1 Protein Expression. To examine the time
course of cyclin D1 protein upregulation by PDGF-BB and
repression by dexamethasone, growth-arrested ASM cells
fromn = 7non-asthmaticandn = 7asthmaticsubjectswere
pretreated for 1h with 100nM dexamethasone, compared to
vehicle. Cells were then stimulated with 25ng/mL PDGF-
BB for 0, 2, 4, 8, and 24h. Cells were lysed, then cyclin D1
was quantiﬁed by western blotting using a rabbit polyclonal
antibodyagainstcyclinD1(M-20:SantaCruzBiotechnology,
Santa Cruz, CA), compared to α-tubulin as the loading con-
trol (mouse monoclonal IgG1, clone DM 1A; Santa Cruz).
Primary antibodies were detected with goat anti-mouse or
anti-rabbit horse-radish peroxidase-conjugated secondary
antibodies (Cell Signaling Technology, Danvers, MA) and
visualized by enhanced chemiluminescence (PerkinElmer,
Wellesley, MA). Densitometry was performed using Image J
[15].
2.4.Translocation. Tomeasuretranslocationoftheglucocor-
ticoid receptor (GR), growth-arrested ASM cells from n = 3
non-asthmatic and n = 3 asthmatic subjects were treated
with vehicle or dexamethasone (100nM) for 1h, prior to
stimulation with 25ng/mL PDGF-BB for 1h. Cytoplasmic
and nuclear protein extraction was performed using NE-
PER nuclear and cytosolic extraction kit according to the
manufacturer’s instructions (Thermo Fisher Scientiﬁc,
Rockford, IL). GR was quantiﬁed by western blotting using
a rabbit polyclonal antibody against GR (E-20: Santa Cruz
Biotechnology) compared to α-tubulin and a rabbit poly-
clonal antibody to lamin A/C (cell signaling technology) as
a loading control for the cytosolic and nuclear fractions,
respectively.
2.5. Statistical Analysis. Statistical analysis was performed
using either the Student’s unpaired t-test, or one-way orJournal of Allergy 3
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Figure 1: PDGF-BB upregulates cyclin D1 mRNA and protein
expression in ASM from nonasthmatics and asthmatics. ASM
cells from non-asthmatics and asthmatics were stimulated with
25ng/mL of mitogen PDGF-BB. (a) demonstrates the temporal
kinetics of cyclin D1 mRNA expression quantiﬁed by real-time
RT-PCR (expressed as fold increase over 0h). Statistical analysis
was performed using one-way ANOVA, followed by Fisher’s post
hoc multiple comparison test (∗ denotes a signiﬁcant eﬀect of
PDGF-BB on cyclin D1 mRNA, compared to 0h (P<0.05)). (b)
shows densitometric analysis of cyclin D1 protein expression at
24h quantiﬁed by western blotting (expressed as fold increase over
0h), using α-tubulin as the loading control. Statistical analysis was
performed using the Student’s unpaired t-test (where ∗ denotes a
signiﬁcant eﬀect of PDGF-BB on cyclin D1 protein, compared to
0h(P<0.05)). Values are mean + SE.
two-way ANOVA followed by Fisher’s post hoc multiple
comparison test. P values < 0.05 were suﬃc i e n tt or e j e c tt h e
null hypothesis for all analyses.
3. Results
To examine the time course of induction of cyclin D1
mRNAbythemitogenPDGF-BB,growth-arrestedASMcells
from non-asthmatic and asthmatic subjects were stimulated
with PDGF-BB for up to 24h. As shown in Figure 1(a),
a signiﬁcant increase in cyclin D1 mRNA expression was
ﬁrst detected 8h after PDGF-BB treatment. By 24h, cyclin
D1 mRNA expression had further signiﬁcantly increased to
2.6±0.3-foldinASMcellsfromnon-asthmaticsand2.9±0.3-
fold in cells from asthmatics (P<0.05). Interestingly, there
was no signiﬁcant diﬀerence between the increases in cyclin
D1 upregulation in cells from asthmatics, as compared to
nonasthmatic controls. Cyclin D1 protein expression at 24h
was similarly upregulated in support of the mRNA data
Figure 1(b). Interestingly, there were no signiﬁcant diﬀer-
ences between the amount of cyclin D1 mRNA and protein
expressionintheasthmatics,ascomparedtonon-asthmatics.
We then examined the eﬀect of the corticosteroid dex-
amethasone on the temporal kinetics of PDGF-BB-induced
cyclin D1 mRNA and protein expression in ASM cells from
asthmatics and non-asthmatics. Growth-arrested ASM cells
were pretreated for 1h with vehicle or 100nM dexametha-
sone and stimulated with PDGF-BB for up to 24h. In ASM
cellsfromnon-asthmatics,thecorticosteroiddexamethasone
signiﬁcantly inhibited cyclin D1 mRNA upregulation in
responsetoPDGF-BBstimulation(Figure 2(a),P<0.05).As
shown in Figure 2(a), 100nM dexamethasone signiﬁcantly
inhibitedtheamountofPDGF-BB-inducedcyclinD1mRNA
expression at 8h and 24h after stimulation (Figure 2(a);
P<0.05), and a resultant attenuation of cyclin D1 protein
expression was also observed at 24h (Figure 2(b); P<0.05).
In contrast, parallel experiments performed in ASM
cells from asthmatics revealed that the PDGF-BB-induced
upregulation of cyclin D1 mRNA and protein expression
was resistant to inhibition by dexamethasone (Figure 3). As
shown in Figure 3(a), there was no signiﬁcant diﬀerence in
thetemporalkineticsofPDGF-BB-inducedcyclinD1mRNA
expression in the presence or absence of dexamethasone.
Moreover,therewerenosigniﬁcantdiﬀerencesinamountsof
PDGF-BB-induced cyclin D1 protein induced after pretreat-
ment with dexamethasone (1.5 ± 0.2-fold), as compared to
vehicle control (1.5 ± 0.2-fold) (Figure 3(b)).
To examine whether the degree of GR nuclear translo-
cation diﬀered in mitogen-treated ASM from asthmatics as
compared to non-asthmatics, cells were pretreated with dex-
amethasone for 1h, stimulated with PDGF-BB for 1h, prior
to preparation of puriﬁed nuclear and cytoplasmic extracts.
As shown in Figure 4, dexamethasone induced the transloca-
tion of GR to a similar extent in cells from non-asthmatics
(Figure 4(a)), compared to asthmatics (Figure 4(b)). PDGF-
BB had no eﬀect on the degree of GR nuclear translocation
induced by dexamethasone.
4. Discussion
Increase in airway smooth muscle mass is a hallmark of the
remodelled airway in asthma. Many studies have focused
on the G1-to-S transition, in particular the role of cyclin
D1 in modulating G1 progression to S-phase traversal in
ASM cells from non-asthmatics. Our study examines cyclin
D1 in ASM from asthmatic subjects, and compares the
relative inhibitory eﬃcacy of corticosteroids with ASM cells
from non-asthmatics. We have conﬁrmed that cyclin D1
upregulation in ASM cells is inhibited by corticosteroids
[16]. We are the ﬁrst to examine the eﬀect of dexamethasone4 Journal of Allergy
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Figure 2: Dexamethasone inhibits cyclin D1 mRNA and protein
expression in ASM cells from non-asthmatics. ASM cells from non-
asthmatics (n = 7 − 8) were pretreated for 1h with vehicle or
dexamethasone and then stimulated with 25ng/mL PDGF-BB. (a)
demonstrates the eﬀect of dexamethasone on the temporal kinetics
of PDGF-BB-induced cyclin D1 mRNA expression (expressed as
foldincreaseover0h).Statisticalanalysiswasperformedusingtwo-
way ANOVA, followed by Fisher’s post hoc multiple comparison
test (where ∗ denotes signiﬁcant inhibition by dexamethasone
(P<0.05)). (b) shows densitometric analysis of the eﬀect of
dexamethasone on cyclin D1 protein (expressed as fold increase
over 0h), using α-tubulin as the loading control. Statistical analysis
wasperformedusingtheStudent’sunpairedt-test(where ∗denotes
a signiﬁcant inhibition by dexamethasone (P<0.05)). Values are
mean + SE.
on the mitogen PDGF-BB-induced cyclin D1 upregulation
in ASM cells from both non-asthmatics and asthmatics.
Intriguingly, we show that we are unable to totally inhibit
cyclin D1 mRNA and protein upregulation in cells from
asthmaticsubjects.Theseresultscorroborateearlierevidence
demonstrating that corticosteroid-inhibited proliferation
occurs only in ASM cells from subjects without asthma
[8] and suggest that there are corticosteroid insensitive
proliferative pathways in asthmatics that warrant further
investigation in order to design eﬃcacious antiremodelling
strategies.
How ASM mass increases in a remodelled airway is an
area under intense investigation. In vivo, there is evidence
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Figure 3: Cyclin D1 mRNA and protein expression in ASM
cells from asthmatics were relatively resistant to inhibition by
dexamethasone. ASM cells from asthmatics (n = 7) were pretreated
for 1h with vehicle or dexamethasone and then stimulated with
25ng/mL PDGF-BB. (a) demonstrates the eﬀect of dexamethasone
on the temporal kinetics of PDGF-BB-induced cyclin D1 mRNA
expression (expressed as fold increase over 0h). (b) shows densito-
metric analysis of the eﬀect of dexamethasone on cyclin D1 protein
(expressed as fold increase over h), using α-tubulin as the loading
control. Values are mean + SE.
of greater ASM cell number (hyperplasia) [17, 18].I nv i t r o ,
hyperplasia of ASM is well supported by numerous in vitro
studies in which ASMs have been shown to proliferate in
responsetomitogenicinﬂammatorymediatorspresentinthe
inﬂamed airways (reviewed in [4, 9, 10]), and by the obser-
vation that ASM cells from asthmatics have a greater rate
of proliferation in vitro when compared to cells from non-
asthmatics [13, 19]. Cyclin D1 upregulation, and its repres-
sion by corticosteroids, has been extensively examined in in
vitrostudies using cells from non-asthmatics (reviewed in [4,
9, 10]). Our study compares and contrasts the upregulation
of cyclin D1, and the relative eﬃcacy of corticosteroids, in
cells from both asthmatics and non-asthmatics examined
in vitro. We observe corticosteroid insensitivity in cells
from asthmatics. This insensitivity was not due to altered
nuclear translocation of the glucocorticoid receptor in ASM
cells from asthmatics compared to non-asthmatics. Rather,Journal of Allergy 5
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Figure 4: Dexamethasone-induced GR nuclear translocation does not diﬀer between mitogen-treated ASM from asthmatics as compared to
non-asthmatics. ASM cells from (a) n = 3 non-asthmatics or (b) n = 3 asthmatics were pretreated for 1h with vehicle or dexamethasone
(100nM) and then stimulated for 1h with 25ng/mL PDGF-BB. Cytoplasmic (CYT) and nuclear (NUC) fractions were prepared, and GR
protein was measured by western blotting (representative blots illustrated), using α-tubulin and lamin A/C as the loading controls for the
cytoplasmic or nuclear fractions, respectively.
a number of studies may have posed some possible expla-
nations for our observations. ASM cells are tethered within
the extracellular-matrix- (ECM-) rich microenvironment of
ﬁbrotic asthmatic airway. In asthma, the abundance of ECM
proteins, including collagen I, is increased [20]. Bonaccci et
al. [21] demonstrated that integrin/collagen I interactions
impaired the antimitogenic action of dexamethasone. As
ASM cells from asthmatics secrete greater amounts of colla-
gen I than non-asthmatics, integrin/ECM interactions may
contribute to corticosteroid resistance in our experiments.
As an alternative explanation, Roth et al. [8] demonstrated
that the antiproliferative eﬀect of corticosteroids in ASM
cells requires the formation of a complex between the
glucocorticoid receptor and the CCAAT/enhancer binding
proteinalpha(C/EBPα).AsC/EBPαproteinisabsentinASM
cells from asthmatics, interaction of corticosteroid with its
cognate receptor would be unable to form the required anti-
mitogenic complex, explaining the failure of corticosteroids
to inhibit cyclin D1-mediated proliferative pathways in vitro.
In summary, we have shown that cyclin D1 mRNA and
protein upregulation in asthmatic ASM cells are insensitive
to inhibition by corticosteroids. Our results may reﬂect the
contribution of impaired corticosteroid action via ASM-
ECM interactions or absence of a key transcriptional
regulator of corticosteroid action (C/EBPα) in asthmatic
cells. Which possibility is responsible for corticosteroid
insensitivity in ASM cells from asthmatics is unknown at
present, but this observation underscores the importance
of investigations into underlying molecular mechanisms of
ASM hyperplasia in asthma to allow future development
of eﬃcacious antiremodelling strategies as future asthma
pharmacotherapeutics.
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